Osteoarthritis therapeutic - LG Life SciencesAlternative Names: Synovian
Latest Information Update: 08 Oct 2015
At a glance
- Originator LG Life Sciences
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Osteoarthritis
Most Recent Events
- 28 Aug 2015 Phase-III clinical trials in Osteoarthritis in South Korea (unspecified route)